EPISODE · Jun 5, 2026 · 11 MIN
MPR Weekly Dose Podcast #277 — Treatment Approved for cUTI; COVID-19 Postexposure Prophylaxis; Eye Drops Fail to Meet Endpoint; Afrezza Indication Expanded; Obefazimod UC Trial Results
from MPR Weekly Dose
New treatment approved for adults with complicated urinary tract infections; Xocova approved for COVID-19 postexposure prophylaxis; investigational diabetic macular edema eye drop fails to meet trial endpoint; Afrezza expanded for pediatric use; obefazimod looks promising for ulcerative colitis.
Embed this episode
Ready to play
MPR Weekly Dose Podcast #277 — Treatment Approved for cUTI; COVID-19 Postexposure Prophylaxis; Eye Drops Fail to Meet Endpoint; Afrezza Indication Expanded; Obefazimod UC Trial Results
0:00
11:45
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of MPR Weekly Dose?
This episode is 11 minutes long.
When was this MPR Weekly Dose episode published?
This episode was published on June 5, 2026.
Can I download this MPR Weekly Dose episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!